OncLive TV

Matthew H. Taylor, MD, discusses the preliminary data on the use of IO-108 in advanced solid tumors in a phase 1 study.

Heather Han, MD, discusses prior research with gedatolisib that provided the rationale for the phase 3 VIKTORIA-1 trial (NCT05501886) in patients with hormone receptor (HR)–positive, HER2-negative metastatic breast cancer.

Rahul Aggarwal, MD, discusses key findings from a phase 2a trial evaluating the combination of BXCL701 and pembrolizumab in patients with metastatic castration-resistant prostate cancer with the small cell neuroendocrine cancer phenotype.

Michael Shusterman, MD, discusses findings from a retrospective study to determine the feasibility of a novel genome-wide methylome enrichment platform for the early detection of multiple solid tumors.

Niveditha Nerlakanti, discusses the investigation of HDAC inhibitors in osteosarcoma.

Marilena Tauro, PhD, discusses the role for ULK3 in regulating autophagy in multiple myeloma.

Paul Stewart, PhD, discusses the multiomic landscape of squamous cell lung cancer.

Yiming Wu, PhD, discusses a study identifying METTL3-mediated N6-methyladenosine modification as a key translational regulator of splicing factors, and how this mechanism contributes to the progression of chronic lymphocytic leukemia.

Mostafa Nasr, PhD candidate, discusses the development of novel preclinical models of prostate cancer dormancy, and the significance of these outcomes may have on future research in metastatic prostate cancer.

Cassandra A. Hathaway, MD, discusses the rationale for investigating the association between distress, such as depression, and the tumor immune microenvironment in patients with ovarian cancer.

Ranjit S. Bindra, MD, PhD, discusses a new class of DNA modifiers which selectively target tumor DNA with the goal of overcoming resistance mechanisms across multiple types of cancer.

Diane M. Simeone, MD, discusses the phase 1/2 EVEREST-1 trial evaluating the autologous CAR T-cell therapy A2B530 in patients with solid tumors.

Julia E. McGuinness, MD, discusses combating gastrointestinal toxicities in PI3K-mutated breast cancer.

Ana Alfonso Piérola, MD, PhD, discusses unmet needs for patients with high-risk myelodysplastic syndrome.

Adana A.M. Llanos, PhD, MPH, discusses the relationship between prediagnostic allostatic load and breast cancer clinicopathology in Black women.

Sangeetha Venugopal, MD, MS, discusses the importance of increasing awareness of blastic plasmacytoid dendritic cell neoplasm to improve early diagnosis and treatment for patients with BPDCN at academic centers.

Harikrishna Nakshatri, BVSc, PhD, discusses the investigation of TONSL in patients with breast cancer.

Roy S. Herbst, MD, PhD, discusses the implications of the phase 3 AEGEAN trial in patients with resectable non–small cell lung cancer.

Edward B. Garon, MD, MS, discusses challenges associated with the incorporation of immunotherapy into the treatment paradigm for EGFR-mutant non–small cell lung cancer.

Ryan J. Sullivan, MD, explains the prolongation of survival with tebentafusp-tebn despite apparent initial radiographic tumor progression in patients with uveal melanoma.

Ryan J. Sullivan, MD, discusses findings from a study investigating the effects of early circulating tumor DNA reduction on overall survival in patients with uveal melanoma treated with tebentafusp.

Giovanni Marconi, MD, discusses ongoing research with the combination of tamibarotene and azacitidine in patients with higher-risk myelodysplastic syndrome.

Erika P. Hamilton, MD, director, Breast and Gynecologic Cancer Research, Sarah Cannon Research Institute, discusses the potential of the PI3K inhibitor RLY-2608 in PI3K-mutated breast cancer.

Ahmed O. Kaseb, MD, discusses the significance of results from the phase 3 IMbrave050 trial of adjuvant atezolizumab and bevacizumab for patients with early-stage hepatocellular carcinoma.

Karen L. Reckamp, MD, MS, discusses updated findings from the phase 2 LCMC3 trial in resectable stage IB to IIIB non–small cell lung cancer.

Melinda Butsch Kovacic, MPH, PhD; Elizabeth Shaughnessy, MD, PhD; Sandra L. Starnes, MD; and Susan E. Waltz, PhD, discuss the advice they would give to their younger selves and future female oncology professionals, knowing what they know now about the oncology field and their own career growth.

Melinda Butsch Kovacic, MPH, PhD; Elizabeth Shaughnessy, MD, PhD; Sandra L. Starnes, MD; and Susan E. Waltz, PhD, discuss challenges they faced throughout their early careers and how some of those challenges continue to affect the professional lives of female physicians.

Jason J. Luke, MD, FACP, discusses initial results from the phase 1 GLIMMER-01 trial of E-602 in advanced solid tumors.

Foluso Bisi Ademuyiwa, MD, MPH, MSCI, discusses the optimal sequencing of current CDK4/6 inhibitors in the first-line setting for hormone receptor (HR)–positive, HER2-negative breast cancer based on updated efficacy and safety data.

Estelamari Rodriguez, MD, MPH, discusses the benefits of the TKIs afatinib and osimertinib in patients with lung cancer with uncommon EGFR mutations.